Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression
Bone/bone marrow metastasis seems to be more sensible to this treatment compared to soft tissue lesions and the percentage of GD2-positive tumor cells tends to decrease under chemoimmunotherapy pressure.